843653-04-3Relevant articles and documents
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
Rotella, David P.,McFarlane, Geraldine R.,Greenfield, Alexander,Grosanu, Cristina,Robichaud, Albert J.,Denny, Rajiah Aldrin,Feenstra, Rolf W.,Nunez-Garcia, Sara,Reinders, Jan-Hendrik,Neut, Martina van der,McCreary, Andrew,Kruse, Chris G.,Sullivan, Kelly,Pruthi, Farhana,Lai, Margaret,Zhang, Jean,Kowal, Dianne M.,Carrick, Tikva,Grauer, Steven M.,Navarra, Rachel L.,Graf, Radka,Brennan, Julie,Marquis, Karen L.,Pausch, Mark H.
, p. 5552 - 5555 (2009)
A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays.
Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2
Hatzenbuhler, Nicole T.,Baudy, Reinhardt,Evrard, Deborah A.,Failli, Amedeo,Harrison, Boyd L.,Lenicek, Steven,Mewshaw, Richard E.,Saab, Annmarie,Shah, Uresh,Sze, Jean,Zhang, Minsheng,Zhou, Dahui,Chlenov, Michael,Kagan, Michael,Golembieski, Jeannette,Hornby, Geoffrey,Lai, Margaret,Smith, Deborah L.,Sullivan, Kelly M.,Schechter, Lee E.,Andree, Terrance H.
experimental part, p. 6980 - 7004 (2009/11/30)
Novel compounds combining a 5-HT1A moiety (3-aminochroman scaffold) and a 5-HT transporter (indole analogues) linked through a common basic nitrogen via an alkyl chain attached at the 1- or 3-position of the indole were evaluated for dual affin
3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES
-
Page/Page column 91, (2010/02/10)
3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.
